Scarica l'app Stockscreener
63.63
0.89%
-0.57
Dopo l'orario di chiusura:
63.00
-0.63
-0.99%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$64.20
Aprire:
$63.73
Volume 24 ore:
1.75M
Relative Volume:
0.92
Capitalizzazione di mercato:
$7.84B
Reddito:
$18.47M
Utile/perdita netta:
$-589.53M
Rapporto P/E:
-12.10
EPS:
-5.26
Flusso di cassa netto:
$-399.80M
1 W Prestazione:
+2.18%
1M Prestazione:
-4.75%
6M Prestazione:
+19.34%
1 anno Prestazione:
+43.31%
Intervallo 1D:
$61.46
$63.83
Intervallo di 1 settimana:
$59.63
$64.68
Portata 52W:
$29.31
$70.98
Cytokinetics Inc Stock (CYTK) Company Profile
Nome
Cytokinetics Inc
Settore
Industria
Telefono
(650) 624-3000
Indirizzo
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
63.63 | 7.91B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.38 | 126.81B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
774.66 | 81.62B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.09 | 45.97B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.43 | 42.76B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
298.91 | 33.88B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-12-18 | Aggiornamento | Goldman | Neutral → Buy |
| 2025-07-30 | Ripresa | Raymond James | Mkt Perform |
| 2025-04-24 | Iniziato | Barclays | Overweight |
| 2025-02-07 | Iniziato | Citigroup | Buy |
| 2025-01-22 | Iniziato | Stifel | Buy |
| 2024-11-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-13 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2024-01-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-07 | Iniziato | B. Riley Securities | Buy |
| 2023-08-15 | Iniziato | SVB Securities | Outperform |
| 2023-02-17 | Iniziato | BofA Securities | Neutral |
| 2022-12-23 | Reiterato | Needham | Buy |
| 2022-12-20 | Iniziato | Truist | Buy |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-01-28 | Iniziato | Goldman | Buy |
| 2021-12-22 | Iniziato | Oppenheimer | Outperform |
| 2021-12-10 | Iniziato | JP Morgan | Overweight |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2021-02-18 | Iniziato | Barclays | Overweight |
| 2021-01-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-29 | Iniziato | Goldman | Neutral |
| 2020-07-10 | Iniziato | Raymond James | Strong Buy |
| 2020-05-05 | Iniziato | Mizuho | Buy |
| 2020-04-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Ripresa | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Reiterato | Morgan Stanley | Overweight |
| 2017-11-22 | Downgrade | Needham | Strong Buy → Buy |
| 2017-11-21 | Reiterato | H.C. Wainwright | Buy |
| 2017-07-31 | Iniziato | Morgan Stanley | Overweight |
| 2017-03-08 | Iniziato | Rodman & Renshaw | Buy |
| 2017-02-06 | Aggiornamento | Needham | Buy → Strong Buy |
| 2016-12-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Reiterato | Needham | Buy |
| 2015-11-10 | Reiterato | FBR Capital | Outperform |
| 2015-11-09 | Reiterato | ROTH Capital | Buy |
| 2015-07-24 | Reiterato | MLV & Co | Buy |
| 2014-12-31 | Reiterato | ROTH Capital | Buy |
| 2014-11-04 | Aggiornamento | MLV & Co | Hold → Buy |
| 2014-04-28 | Reiterato | Needham | Buy |
Mostra tutto
Cytokinetics Inc Borsa (CYTK) Ultime notizie
Cytokinetics at Barclays Conference: Strategic Growth and Global Ambitions - Investing.com
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Leerink Maintains Outperform for Cytokinetics, Incorporated (CYTK) March 2026 - Meyka
Robert Blum Sells 7,931 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Cytokinetics (NASDAQ:CYTK) EVP Sells $156,779.04 in Stock - MarketBeat
Cytokinetics Leaders Gained $16 Million as Insiders, Suit Says - Bloomberg Law News
Cytokinetics at The Citizens Life Sciences Conference: Myqorzo’s Market Potential - Investing.com Canada
Leerink reiterates Cytokinetics stock rating on launch confidence By Investing.com - Investing.com Canada
Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market - Yahoo Finance
Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market - The Motley Fool
Cytokinetics at Leerink Global Healthcare Conference: Strategic Growth in Cardiology - Investing.com Canada
UBS Maintains Neutral on CYTK, Cytokinetics, Incorporated March 2026 - Meyka
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Leerink Partners Global Biopharma Conference 2026: TEVA, CYTK, IMRX, TNYA And More Set To Present - RTTNews
Rhenman & Partners Asset Management AB Raises Stake in Cytokinetics, Incorporated $CYTK - MarketBeat
Knott David M Jr Purchases Shares of 30,000 Cytokinetics, Incorporated $CYTK - MarketBeat
GW&K Investment Management LLC Takes $9.93 Million Position in Cytokinetics, Incorporated $CYTK - MarketBeat
GABELLI & Co INVESTMENT ADVISERS INC. Makes New $2.06 Million Investment in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics (CYTK) Analyst Rating: UBS Raises Price Target to $69.00 | CYTK Stock News - GuruFocus
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Ascendis Pharma (ASND) and Avalo Therapeutics (AVTX) - The Globe and Mail
Callos, Cytokinetics EVP, sells $1.6 million in CYTK stock - Investing.com UK
Callos, Cytokinetics EVP, sells $1.6 million in CYTK stock By Investing.com - Investing.com Canada
Cytokinetics: From Aficamten Trials to MYQORZO Launch—A High-Stakes Race in the HCM Market! - Smartkarma
Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos Sells 26,000 Shares - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Investors to Inquire about Securities Investigation - ACCESS Newswire
Segall Bryant & Hamill LLC Boosts Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Royce & Associates LP Invests $5.50 Million in Cytokinetics, Incorporated $CYTK - MarketBeat
Legato Capital Management LLC Takes Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Fisher Asset Management LLC Raises Stock Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics Is Priced For A Big MYQORZO Launch - Finimize
Rafferty Asset Management LLC Has $5.72 Million Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
CYTK Should I Buy - Intellectia AI
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Cytokinetics Wins Dual MYQORZO Approvals But Faces Execution And Loss Risks - simplywall.st
Insider Sell: B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
EVP at Cytokinetics (NASDAQ: CYTK) sells 886 shares after option exercise - Stock Titan
[144] CYTOKINETICS INC SEC Filing - Stock Titan
Director Lynne Parshall trims Cytokinetics (CYTK) stake in sale - Stock Titan
Cytokinetics to Participate in March Investor Conferences - The Manila Times
March investor fireside chats: Cytokinetics to webcast - Stock Titan
Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech With A 46.52% Potential Upside - DirectorsTalk Interviews
Cytokinetics, Incorporated $CYTK Stock Position Raised by Handelsbanken Fonder AB - MarketBeat
CYTK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Assessing Cytokinetics (CYTK) Valuation After Recent Share Price Weakness And Aficamten Expectations - Yahoo Finance
A Look At Cytokinetics (CYTK) Valuation After Recent Share Price Pullback - simplywall.st
Monashee Investment Management LLC Buys Shares of 100,000 Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics (HAM:KK3A) Total Receivables : €1.54 Mil (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) Inventories, Raw Materials & Components : €0.00 Mil (As of Sep. 2025) - GuruFocus
TD Asset Management Inc Raises Stake in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics (HAM:KK3A) Inventories, Inventories Adjustments : €0.00 Mil (As of Sep. 2025) - GuruFocus
Cytokinetics (HAM:KK3A) YoY Rev. per Sh. Growth : 250.00% (As of Sep. 2025) - GuruFocus
Cytokinetics Inc Azioni (CYTK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.57%
0.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):